Masters, marionettes and modulators: Intersection of pathogen virulence factors and mammalian death receptor signaling

Current Opinion in Immunology

Volumn 25, Issue 4, 2013, Pages 436-440

  Silke, John ^a,b   Hartland, Elizabeth L ^b,c  

^a WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c ROYAL CHILDREN'S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

DEATH RECEPTOR; FAS ANTIGEN; FAS LIGAND; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR; VIRULENCE FACTOR;

APOPTOSIS; CELL DEATH; CYTOKINE PRODUCTION; ENTEROPATHOGENIC ESCHERICHIA COLI; HOST PATHOGEN INTERACTION; HUMAN; IMMUNE RESPONSE; INFECTION; INFLAMMATION; NONHUMAN; PROTEIN FUNCTION; REVIEW; SHIGELLA; SIGNAL TRANSDUCTION;

ANIMALS; BACTERIAL INFECTIONS; FAS LIGAND PROTEIN; HUMANS; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; SIGNAL TRANSDUCTION; TNF-RELATED APOPTOSIS-INDUCING LIGAND; VIRULENCE FACTORS;

EID: 84884151651     PISSN: 09527915     EISSN: 18790372     Source Type: Journal    
DOI: 10.1016/j.coi.2013.05.011     Document Type: Review

References (38)

1. Gonçalves N.S., Ghaem-Maghami M., Monteleone G., Frankel G., Dougan G., Lewis D.J., Simmons C.P., MacDonald T.T. Critical role for tumor necrosis factor alpha in controlling the number of lumenal pathogenic bacteria and immunopathology in infectious colitis. Infect Immun 2001, 69:6651-6659.
2. Moore T.A., Perry M.L., Getsoian A.G., Monteleon C.L., Cogen A.L., Standiford T.J. Increased mortality and dysregulated cytokine production in tumor necrosis factor receptor 1-deficient mice following systemic Klebsiella pneumoniae infection. Infect Immun 2003, 71:4891-4900.
3. Tian T., Dubin K., Jin Q., Qureshi A., King S.L., Liu L., Jiang X., Murphy G.F., Kupper T.S., Fuhlbrigge R.C. Disruption of TNF-α/TNFR1 function in resident skin cells impairs host immune response against cutaneous vaccinia virus infection. J Invest Dermatol 2012, 132:1425-1434.
4. Benedict C.A. Viruses and the TNF-related cytokines, an evolving battle. Cytokine Growth Factor Rev 2003, 14:349-357.
5. Lamkanfi M., Dixit V.M. Manipulation of host cell death pathways during microbial infections. Cell Host Microbe 2010, 8:44-54.
6. Calkins C.C., Platt K., Potempa J., Travis J. Inactivation of tumor necrosis factor-alpha by proteinases (gingipains) from the periodontal pathogen, Porphyromonas gingivalis. Implications of immune evasion. J Biol Chem. 1998, 273:6611-6614.
7. Mezyk-Kopec R., Bzowska M., Potempa J., Bzowska M., Jura N., Sroka A., Black R.A., Bereta J. Inactivation of membrane tumor necrosis factor alpha by gingipains from Porphyromonas gingivalis. Infect Immun 2005, 73:1506-1514.
8. Alcami A. Viral mimicry of cytokines, chemokines and their receptors. Nat Rev Immunol 2003, 3:36-50.
9. Mohamed M.R., Rahman M.M., Rice A., Moyer R.W., Werden S.J., McFadden G. Cowpox virus expresses a novel ankyrin repeat NF-kappaB inhibitor that controls inflammatory cell influx into virus-infected tissues and is critical for virus pathogenesis. J Virol 2009, 83:9223-9236.
10. Mocarski E.S., Upton J.W., Kaiser W.J. Viral infection and the evolution of caspase 8-regulated apoptotic and necrotic death pathways. Nat Rev Immunol 2012, 12:79-88.
11. Kaiser W.J., Upton J.W., Long A.B., Livingston-Rosanoff D., Daley-Bauer L.P., Hakem R., Caspary T., Mocarski E.S. RIP3 mediates the embryonic lethality of caspase-8-deficient mice. Nature 2011, 471:368-372.
12. Newton H.J., Pearson J.S., Badea L., Kelly M., Lucas M., Holloway G., Wagstaff K.M., Dunstone M.A., Sloan J., Whisstock J.C., et al. The type III effectors NleE and NleB from enteropathogenic E. coli and OspZ from Shigella block nuclear translocation of NF-kappaB p65. PLoS Pathog 2010, 6:e1000898.
13. Zhang L., Ding X., Cui J., Xu H., Chen J., Gong Y.N., Hu L., Zhou Y., Ge J., Lu Q., et al. Cysteine methylation disrupts ubiquitin-chain sensing in NF-κB activation. Nature 2012, 481:204-208.
14. Yen H., Ooka T., Iguchi A., Hayashi T., Sugimoto N., Tobe T. NleC, a type III secretion protease, compromises NF-κB activation by targeting p65/RelA. PLoS Pathog 2010, 6:e1001231.
15. Pearson J.S., Riedmaier P., Marches O., Frankel G., Hartland E.L. A type III effector protease NleC from enteropathogenic Escherichia coli targets NF-kappaB for degradation. Mol Microbiol 2011, 80:219-230.
16. Baruch K., Gur-Arie L., Nadler C., Koby S., Yerushalmi G., Ben-Neriah Y., Yogev O., Shaulian E., Guttman C., Zarivach R., et al. Metalloprotease type III effectors that specifically cleave JNK and NF-κB. EMBO J 2011, 30:221-231.
17. Nadler C., Baruch K., Kobi S., Mills E., Haviv G., Farago M., Alkalay I., Bartfeld S., Meyer T.F., Ben-Neriah Y., et al. The type III secretion effector NleE inhibits NF-kappaB activation. PLoS Pathog 2010, 6:e1000743.
18. Gao X., Wang X., Pham T.H., Feuerbacher L.A., Lubos M.L., Huang M., Olsen R., Mushegian A., Slawson C., Hardwidge P.R. NleB, a bacterial effector with glycosyltransferase activity, targets GAPDH function to inhibit NF-κB activation. Cell Host Microbe 2013, 13:87-99.
19. Girardin S.E., Boneca I.G., Carneiro L.A., Antignac A., Jéhanno M., Viala J., Tedin K., Taha M.K., Labigne A., Zähringer U., et al. Nod1 detects a unique muropeptide from gram-negative bacterial peptidoglycan. Science 2003, 300:1584-1587.
20. Arbibe L., Kim D.W., Batsche E., Pedron T., Mateescu B., Muchardt C., Parsot C., Sansonetti P.J. An injected bacterial effector targets chromatin access for transcription factor NF-kappaB to alter transcription of host genes involved in immune responses. Nat Immunol 2007, 8:47-56.
21. Ashida H., Kim M., Schmidt-Supprian M., Ma A., Ogawa M., Sasakawa C. A bacterial E3 ubiquitin ligase IpaH9.8 targets NEMO/IKKgamma to dampen the host NF-kappaB-mediated inflammatory response. Nat Cell Biol 2010, 12:1-9.
22. Wang F., Jiang Z., Li Y., He X., Zhao J., Yang X., Zhu L., Yin Z., Li X., Wang X., et al. Shigella flexneri T3SS effector IpaH4.5 modulates the host inflammatory response via interaction with NF-κB p65 protein. Cell Microbiol 2013, 15:474-485.
23. Kim D.W., Lenzen G., Page A.L., Legrain P., Sansonetti P.J., Parsot C. The Shigella flexneri effector OspG interferes with innate immune responses by targeting ubiquitin-conjugating enzymes. Proc Natl Acad Sci U S A 2005, 102:14046-14051.
24. Hemrajani C., Berger C.N., Robinson K.S., Marchès O., Mousnier A., Frankel G. NleH effectors interact with Bax inhibitor-1 to block apoptosis during enteropathogenic Escherichia coli infection. Proc Natl Acad Sci U S A 2010, 107:3129-3134.
25. Bergounioux J., Elisee R., Prunier A.L., Donnadieu F., Sperandio B., Sansonetti P., Arbibe L. Calpain activation by the Shigella flexneri effector VirA regulates key steps in the formation and life of the bacterium's epithelial niche. Cell Host Microbe 2012, 11:240-252.
26. Robinson N., McComb S., Mulligan R., Dudani R., Krishnan L., Sad S. Type I interferon induces necroptosis in macrophages during infection with Salmonella enterica serovar Typhimurium. Nat Immunol 2012, 13:954-962.
27. Beutler B., Rietschel E.T. Innate immune sensing and its roots: the story of endotoxin. Nat Rev Immunol 2003, 3:169-176.
28. Aggarwal B.B. Signalling pathways of the TNF superfamily: a double-edged sword. Nat Rev Immunol 2003, 3:745-756.
29. Benedict C.A., Ware C.F. TRAIL: not just for tumors anymore?. J Exp Med 2012, 209:1903-1906.
30. Steinwede K., Henken S., Bohling J., Maus R., Ueberberg B., Brumshagen C., Brincks E.L., Griffith T.S., Welte T., Maus U.A. TNF-related apoptosis-inducing ligand (TRAIL) exerts therapeutic efficacy for the treatment of pneumococcal pneumonia in mice. J Exp Med 2012, 209:1937-1952.
31. Smith W., Tomasec P., Aicheler R., Loewendorf A., Nemčovičová I., Wang E.C., Stanton R.J., Macauley M., Norris P., Willen L., et al. Human cytomegalovirus glycoprotein UL141 targets the TRAIL death receptors to thwart host innate antiviral defenses. Cell Host Microbe 2013, 13:324-335.
32. Peter M.E., Budd R.C., Desbarats J., Hedrick S.M., Hueber A.O., Newell M.K., Owen L.B., Pope R.M., Tschopp J., Wajant H., et al. The CD95 receptor: apoptosis revisited. Cell 2007, 129:447-450.
33. O'Reilly L.A., Tai L., Lee L., Kruse E.A., Grabow S., Fairlie W.D., Haynes N.M., Tarlinton D.M., Zhang J.G., Belz G.T., et al. Membrane-bound Fas ligand only is essential for Fas-induced apoptosis. Nature 2009, 461:659-663.
34. Grassmé H., Kirschnek S., Riethmueller J., Riehle A., von Kürthy G., Lang F., Weller M., Gulbins E. CD95/CD95 ligand interactions on epithelial cells in host defense to Pseudomonas aeruginosa. Science 2000, 290:527-530.
35. Rethi B., Eidsmo L. FasL and TRAIL signaling in the skin during cutaneous leishmaniasis-implications for tissue immunopathology and infectious control. Front Immunol 2012, 3:163.
36. Vutova P., Wirth M., Hippe D., Gross U., Schulze-Osthoff K., Schmitz I., Lüder C.G. Toxoplasma gondii inhibits Fas/CD95-triggered cell death by inducing aberrant processing and degradation of caspase 8. Cell Microbiol 2007, 9:1556-1570.
37. Novak M.T., Bryers J.D., Reichert W.M. Biomimetic strategies based on viruses and bacteria for the development of immune evasive biomaterials. Biomaterials 2009, 30:1989-2005.
38. Wei P., Wong W.W., Park J.S., Corcoran E.E., Peisajovich S.G., Onuffer J.J., Weiss A., Lim W.A. Bacterial virulence proteins as tools to rewire kinase pathways in yeast and immune cells. Nature 2012, 488:384-388.